Sp382
HOW TO INTEGRATE THERAPEUTIC DRUG MONITORING INTO YOUR PRACTICE — LESSONS FROM RECENT STUDIES
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.
Presenter
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
VEDOLIZUMAB RESPONSE IN ULCERATIVE COLITIS ASSOCIATES WITH LYMPHOID AGGREGATE ATTENUATION THROUGH IMPAIRED RECRUITMENT OF NAÏVE LYMPHOCYTES
The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
